PMID- 11374896
OWN - NLM
STAT- MEDLINE
DCOM- 20010719
LR  - 20161124
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 284
IP  - 1
DP  - 2001 Jun 1
TI  - Oxidized LDL-mediated monocyte adhesion to endothelial cells does not involve 
      NFkappaB.
PG  - 239-44
AB  - Oxidised LDL (oxLDL) is a key pathogenic mediator of atherogenesis, exhibiting 
      many proatherogenic properties. We have examined the effect of oxLDL on monocyte 
      adhesion in the endothelial cell line, EA.hy 926. This has included the role of 
      endothelial cell adhesion molecule expression (ICAM-1 and VCAM-1), monocyte 
      chemoattractant protein-1 (MCP-1), and the transcription factor NFkappaB in this 
      interaction. In response to oxLDL (10-100 microg/ml), monocyte adhesion to cells 
      increased dose-dependently. Adhesion of oxLDL at 100 microg/ml was equivalent to 
      that seen with TNFalpha (10 ng/ml). Unmodified LDL (nLDL, 100 microg/ml) had no 
      effect. Both oxLDL and nLDL increased MCP-1 mRNA levels. Interestingly, oxLDL had 
      no effect on the expression of ICAM-1 and VCAM-1. In addition NFkappaB was not 
      activated as shown by western blots of IkappaB-alpha degradation and 
      electrophoretic mobility shift assay. In summary these data show that increased 
      monocyte adhesion to EA.hy 926 cells occurs independently of ICAM-1, VCAM-1, and 
      NFkappaB activation and may involve novel adhesive mechanisms.
CI  - Copyright 2001 Academic Press.
FAU - Dwivedi, A
AU  - Dwivedi A
AD  - Department of Experimental Therapeutics, William Harvey Research Institute, St. 
      Bartholomew's and The Royal London School of Medicine and Dentistry School, Queen 
      Mary University of London, Charterhouse Square, London, EC1M 6BQ, United Kingdom.
FAU - Anggard, E E
AU  - Anggard EE
FAU - Carrier, M J
AU  - Carrier MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Chemokine CCL2)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (NF-kappa B)
RN  - 0 (NFKBIA protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 0 (oxidized low density lipoprotein)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
SB  - IM
MH  - Blotting, Western
MH  - Cell Adhesion/drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Chemokine CCL2/genetics/metabolism
MH  - DNA-Binding Proteins/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Endothelium, Vascular/cytology/*metabolism
MH  - Humans
MH  - *I-kappa B Proteins
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Lipoproteins, LDL/*pharmacology
MH  - Monocytes/cytology/*metabolism
MH  - NF-KappaB Inhibitor alpha
MH  - NF-kappa B/*metabolism
MH  - RNA, Messenger/metabolism
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Vascular Cell Adhesion Molecule-1/metabolism
EDAT- 2001/05/26 10:00
MHDA- 2001/07/20 10:01
CRDT- 2001/05/26 10:00
PHST- 2001/05/26 10:00 [pubmed]
PHST- 2001/07/20 10:01 [medline]
PHST- 2001/05/26 10:00 [entrez]
AID - S0006-291X(01)94955-1 [pii]
AID - 10.1006/bbrc.2001.4955 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2001 Jun 1;284(1):239-44. doi: 
      10.1006/bbrc.2001.4955.